A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs
- Registration Number
- NCT02894918
- Lead Sponsor
- Henan Provincial People's Hospital
- Brief Summary
This study evaluates whether addition of Peginterferon alfa-2a to CHB Patients Treated with nucleoside analogues (NAs) can enhance the rate of HBsAg clearance at end of treatment. This study is a Randomized, open-label, multi-center study.
The CHB patients with NAs treatment and have achieved HBV DNA \<15 IU/ml、HBeAg \<100 PEIU/ml、HBsAg positive and HBsAg\<1500 IU/ml will be randomized into 2 groups:
Group 1 (Combination group): Maintain NAs treatment while add 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 (Mono NA group) : Maintain NAs treatment for 49 weeks. Note: NAs including: LAM, ADV, ETV, or TDF.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 114
- Male and female patients >18 and ≤65 years of age;
- Diagnosed chronic hepatitis B (HBsAg(+) for over 6 months before nucleos(t)ide analogues treatment)
- Patients had achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg positive and HBsAg<1500 IU/ml on treatment of Nucleoside (acid) Analogues (including LAM, ADV, ETV, and TDF )
- Decompensated liver disease: including ascites, hepatic encephalopathy, esophagogastric-varicosis and fissure bleeding and other decompensated complication;
- Hypersensitive to interferon(IFN) or its active substance, and ineligible to IFN;
- A history of immunoregulation drug therapy within 1 year before entry including IFN and so on;
- Coinfection with HAV、HCV、HDV、HEV 、HIV or with Other chronic liver diseases such as Alcoholic Liver Disease,Inherited Metabolic Liver Disease,Drug induced Liver Disease and nonalcoholic fatty liver, autoimmune disease including autoimmune hepatitis and Psoriasis and so on;
- Hepatocellular carcinoma(HCC) or alpha feto protein(AFP) levels more than 100ng/ml and Hepatic malignant potential of Imaging examination or AFP levels more than 100 ng/ml for 3 months;
- A neutrophil count of less than 1500 per cubic millimeter or a platelet count of less than 90,000 per cubic millimeter;
- A serum creatinine level that was more than 1.5 times the upper limit of the normal range;
- With other malignant tumors(exclude the cured ones);
- Severe organ dysfunction;
- With severe psychiatric condition or nervous disease such as epilepsy, depression, mania, epilepsy, schizophrenia and so on;
- Uncontrolled diabetes, hypertension or thyroid disease;
- Pregnant women and lactating women or patients with pregnancy plans and not willing to use contraception during the study period;
- Participate in other clinical studies at the same time;
- Patients unsuitable for the research;
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Combination group Peginterferon alfa-2a Maintain NAs treatment while add 48-week standard treatment by Peginterferon alfa 2a 180µg/week
- Primary Outcome Measures
Name Time Method The rate of HBsAg loss 48 weeks To determine the response rate will be evaluated by HBsAg loss defined as HBsAg level lower than 0.05 IU/ml after 48 week treatment, compared with control group.
- Secondary Outcome Measures
Name Time Method The rate of HBeAg seroconversion 48 weeks Decline of HBeAg quantification 12 weeks, 24 weeks, 48 weeks of treatment Quantitative HBeAg reduction at Weeks 12, 24 and 48 compared with baseline level. Quantitative HBeAg value unit was calculated using 'Paul Ehrlich Institute units per millilitre' (PEIU/ml).
Sustained virological response rate 12 weeks, 24 weeks, 48 weeks of treatment Sustained virological response rate will be presented as rate of HBV DNA \<15 IU/ml
Decline of HBsAg quantification 12 weeks, 24 weeks, 48 weeks of treatment Quantitative HBsAg reduction at Weeks 12, 24 and 48 compared with baseline level. Quantitative HBsAg calculated using 'International Units Per Millilitre' (IU/mL).
The rate of HBeAg loss 48 weeks The rate of HBsAg seroconversion 48 weeks
Trial Locations
- Locations (5)
Weishi County People's Hospital
🇨🇳Kaifeng, Henan, China
Henan People's Hospital
🇨🇳Zhengzhou, Henan, China
Shangqiu No.1 People's Hospital
🇨🇳Shangqiu, Henan, China
Kaifeng Central Hospitl
🇨🇳Kaifeng, Henan, China
Luoyang Central Hospital
🇨🇳Luoyang, Henan, China